Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
02/2010
02/23/2010US7666902 1,1,1,3,3,3-hexachloro-2-methylpropan-2-yl 4-((4-hydroxy-2-oxo-2H-chromen-3-yl)methyl)benzoate; side effect reduction over warfarin
02/23/2010US7666901 -[(Diethylamino)methylene]-7,11-dihydroxy-4-(methoxymethyl)-4a,6a-dimethyl-2,10-dioxo-1,2,4,4a,5,6,6a,7,8,9,9a,10-dodecahydroindeno[4,5-h]isochromen-5-yl acetate; antitumor, -carcinogenic, proliferative agents; imroved antitumor activity; nontoxic; TOR (target of rapamycin) inhibitors
02/23/2010US7666900 ATP-binding cassette transport 1 (ABCA1) stabilizers; using probucol spiroquinone/probucol diphenoquinone as prophylactic/therapeutic agents to decrease ABCA1 expression; low-HDL (high-density lipoprotein) cholesterolemia; arteriosclerosis; pharmacogenetics
02/23/2010US7666899 Administering mitglinide or mitglinide calcium hydrate; hypertriglyceridemia; hypercholesterolemia; hyperlipidemia; anticholesteraol agents; antidiabetic agents; glucose intolerance; non-insulin dependendent diabetes; side effect reduction; cardiovascular disorders
02/23/2010US7666898 Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors
02/23/2010US7666897 Analogs of indole-3-carbinol metabolites as chemotherapeutic and chemopreventive agents
02/23/2010US7666896 improved method; chemical condensation in presence of catalytic hydrogenation catalyst; hydrogenolysis; amidation; angiotensin-converting enzyme (ACE) inhibitor; hypotensive agent for treating hypertension and congestive heart failure
02/23/2010US7666895 adduct comprising a molecule binding with a kinase; antiinflammatory agents; modulating activation state of p38 kinase protein; switch control ligands to induce or restrict conformation
02/23/2010US7666894 comprising oxybutynin and pilocarpine; drug releasing pilocarpine between about 30 minutes to about 60 minutes after oxybutynin is released; treating overactive bladder; urogenital disorders
02/23/2010US7666892 N-{[(4S)-2,5-dioxoimidazolidinyl]methyl}-4-(4-fluorophenoxy)benzenesulfonamide and N-{[(4S)-2,5-dioxoimidazolidinyl]methyl}[1,1'-biphenyl]-4-sulfonamide; chemical intermediates for enzyme inhibitors; especially as inhibitors of MMP12
02/23/2010US7666891 Succinic acid mono-{3-[3-(3-cyano-5-difluoromethyl-phenoxy)-4-ethyl-2-fluoro-benzyl]-4-methyl-5-oxo-4,5-dihydro-[1,2,4]triazol-1-ylmethyl}ester; treating diseases mediated by human immunodeficiency virus inhibit HIV.
02/23/2010US7666890 Synthesis and herbicidal activity of 1- (2-substituted benzo[d]thiazol-5-yl)-1H-1,2,4-triazol-5(4H)- one derivatives
02/23/2010US7666889 Cardiometabolic disorders like obesity, diabetes, hypertension and dyslipidemias, 3, 4-diarylpyrazole derivatives; highly selective; limited or no CNS adverse side effects, including mood disorders
02/23/2010US7666888 (5-(4-Chlorophenyl)isoxazol-4-yl)(3-(pyridin-3-yl)pyrrolidin-1-yl)methanone; enzyme inhibitor of Hydroxysteroid dehydrogenases; treatment of diabetes, obesity
02/23/2010US7666887 Stable, neutral pH, VOC-free biocidal compositions of 1,2-benzisothiazolin-3-one
02/23/2010US7666886 Compounds and methods for the diagnosis and treatment of amyloid associated diseases
02/23/2010US7666885 Enzyme inhibitors
02/23/2010US7666884 N-(2-substituted phenyl)-N-methoxycarbamates and their preparation and use thereof
02/23/2010US7666883 2-[(2-Chloro-5-methyl pyridine-3-yl)(hydroxy)methyl]acrylonitrile; against chloroquine sensitive and chloroquine resistant Plasmodium falciparum; treating malarial; chemical preparation
02/23/2010US7666882 1-(3-Chloro-2-pyridinyl)-N-[2,4-dichloro-6-[[(1-methylethyl)amino]carbonyl]phenyl]-3-(2-propynyloxy)-1H-pyrazole-5-carboxamide; controlling an invertebrate pest; less costly, less toxic, environmentally safer
02/23/2010US7666881 4-(4-(4-(Hydroxydiphenylmethyl)-1-piperidinyl)-1-hydroxybutyl)-alpha,alpha -dimethylbenzene acetic acid hydrochloride formed by azeotropic distillation
02/23/2010US7666880 Hydroxamate compounds which are inhibitors of histone deacetylase; may be useful as medicaments for treatment of proliferative disorders as well as other diseases involving, relating to, or associated with enzymes having histone deacetylase activities such as neurodegenerative, cardiovascular disorders
02/23/2010US7666879 enzyme inhibitor; 2-{2-Fluoro-4-[7-(2-methyl-pyridin-4-yl)-imidazo[1,2-a]pyridin-3-yl]-phenyl}-N-(3-trifluoromethyl-phenyl)-acetamide; angiogenesis inhibitor; antitumor agent; treating hyperglycemia, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, autoimmune diseases, inflammation, and eye disorders
02/23/2010US7666878 Pyrrolopyridine derivatives and their use as Crth2 antagonists
02/23/2010US7666877 Ergoline derivatives
02/23/2010US7666876 Buprenorphine formulations for intranasal delivery
02/23/2010US7666875 Hydantoin compounds
02/23/2010US7666874 hypereosinophilic syndrome with resistance to imatinib
02/23/2010US7666873 N-phenyl-(2R,5S)dimethylpiperazine derivative
02/23/2010US7666872 Use for PDE5 inhibitors
02/23/2010US7666871 3-Methyl-6-(4-{5-methyl-4-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-oxazol-2-yl}-phenyl)-pyridazine; for treatment of obesity, cognitive deficiencies, narcolepsy
02/23/2010US7666870 4-[5-(piperazine-1-carbonyl)-pyridin-2-ylmethyl]-2H-phthalazin-1-one; enzyme inhibitor of poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1); anticarcinogenic agent with BRCA2 deficient phenotype; septic shock; ischemic injury; hemorrhagic shock; and multiple sclerosis
02/23/2010US7666869 Nitrogen-containing 5-membered ring compound
02/23/2010US7666868 N-sulphonylpyrroles and their use as histone deacetylase inhibitors
02/23/2010US7666867 Heteroindanes: a new class of potent cannabimimetic ligands
02/23/2010US7666866 Antithrombotic diamides
02/23/2010US7666865 Calcium channel blockers
02/23/2010US7666864 Bicyclic nitroimidazole-substituted phenyl oxazolidinones
02/23/2010US7666863 Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases
02/23/2010US7666862 2,4-Diphenyl-1-(hexamethylenimin-4-ylaminocarbonyl)dihydropyrrole derivatives that are useful for treating cancer
02/23/2010US7666861 Cytoskeletal active compounds, composition and use
02/23/2010US7666860 Melt-formulated, multi-particulate oral dosage form
02/23/2010US7666859 Skin compositions containing hydrocortisone
02/23/2010US7666858 Pharmaceutical composition for treatment of phimosis using topical corticosteroid
02/23/2010US7666857 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3′-(1h-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
02/23/2010US7666856 Antiviral nucleosides
02/23/2010US7666855 Hepatitis C viral infection; 4-amino-7-(2', 3'-carbonyl-cis-5'-O-[4-(S)-(3-chlorophenyl)-2-oxo-1,3,2-dioxaphosphorinan-2-yl]-2'-C-methyl-beta-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine
02/23/2010US7666854 Bis-modified bicyclic nucleic acid analogs
02/23/2010US7666851 Three ring fused analogs of isoguanosine
02/23/2010US7666849 Ribosome structure and protein synthesis inhibitors
02/23/2010US7666848 such as 3-(4-Methoxy-phenyl)-1-[3-(3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-thiophen-2-yl]-propan-1-one; for use as antidiabetics
02/23/2010US7666847 Medicament comprising a reducing alkyl-sugar monomer for the treatment of inflammatory disorders
02/23/2010US7666846 a conjugate of chloesterol containing compound having a sugar moiety containing methyl esteralkyleneazide group and a carrier protein; produce an effective vaccine to prevent Lyme disease
02/23/2010US7666845 Compounds having inhibitory activity against sodium-dependent glucose transporter
02/23/2010US7666843 Methods and compositions for treatment of neurological disorder
02/23/2010US7666839 Methods of treatment using specific binding agents of human angiopoietin-2
02/23/2010US7666836 administering a luteinizing hormone releasing hormone antagonist selected from cetrorelix, teverelix, ganirelix, antide, abarelix etc. in the form of a short term induction treatment for a period of about 4 to 12 weeks to a patient for treating eddometriosis
02/23/2010US7666832 Administering peptibodies, i.e., peptides fused to other molecules such as an Fc domain of an antibody, where the peptide moiety specifically binds to Ang-2 ( angiopoietin-2); antiinflammatory agent; antirheumatic agent
02/23/2010US7666831 Administering peptibodies, i.e., peptides fused to other molecules such as an Fc domain of an antibody, where the peptide moiety specifically binds to Ang-2 ( angiopoietin-2); antiinflammatory agent; antirheumatic agent
02/23/2010US7666829 Compositions for elastogenesis and connective tissue treatment
02/23/2010US7666674 Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
02/23/2010US7666657 Method for production of arachidonic acid
02/23/2010US7666647 Unphosphorylated glycogen synthase kinase-3-g-beta (GSK) from baculovirus overexpression system; competitive binding; diabetes, Alzheimer's disease
02/23/2010US7666639 Plant deoxyribonucleoside kinase enzymes and their use
02/23/2010US7666638 Preparing selenium-enriched biomass having Se-methionine content of at least 11.39 ng/mgd.w. by culturing microorganisms selected from Lactobacillus reuteri DSM16143, Lactobacillus ferintoshensis DSM16144 and Lactobacillus buchneri/parabuchneri DSM16341 in culture medium comprising selenium salt
02/23/2010US7666619 Compounds and methods for regulating bacterial growth and pathogenesis
02/23/2010US7666444 Organic amine salt of closantel; administered with carrier and optionally macrocyclic lactone; bioavailability, blood concentration; veterinary medicine
02/23/2010US7666442 Topical compositions comprising benfotiamine and pyridoxamine
02/23/2010US7666433 Recombinant RSV strains with altered G protein
02/23/2010US7666410 incorporates a composition containing alumina to which various functional materials containing particular moieties may be adsorbed onto the alumina and used as desired such as pharmaceuticals, xenobiotics, anti-microbial agents, anti-viral agents
02/23/2010US7666409 Soy sauce comprising 3.55% or less by weight of sodium, 0.5-4.2% by weight of potassium, and 0.05-10% by weight of a food material having an antihypertensive effect, wherein remaining portion of liquid seasoning is adapted by incorporation of a substance having nitrogen content of 1.6% or more
02/23/2010US7666400 PEGylation by the dock and lock (DNL) technique
02/23/2010US7666398 Polyanhydride linkers for production of drug polymers and drug polymer compositions produced thereby
02/23/2010US7666395 Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
02/23/2010US7666209 Spine distraction implant and method
02/23/2010CA2548811C Drug and food or drink for improving hyperglycemia
02/23/2010CA2541814C Pharmaceutical compositions comprising malonamide derivatives for decreasing sebum production
02/23/2010CA2539027C Pharmaceutical combinations of hydrocodone and naltrexone
02/23/2010CA2520026C High drug load mesalazine sachet
02/23/2010CA2502109C 4'-c-substituted-2-haloadenosine derivative
02/23/2010CA2498934C Compositions for inducing increased levels of .beta.-chemokines and methods of use therefor
02/23/2010CA2498489C Method for subretinal administration of therapeutics including steroids;method for localizing pharmacodynamic action at the choroid and the retina; and related methods for treatment and/or prevention of retinal diseases
02/23/2010CA2470492C Aqueous compositions containing metronidazole
02/23/2010CA2468234C Acetyl l-carnitine fumarate and process for preparing the same
02/23/2010CA2463446C Use of (11.beta., 17.beta.)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one in the treatment of major depressive disorder
02/23/2010CA2462289C Heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5
02/23/2010CA2448596C Topical treatments using alkanolamines
02/23/2010CA2447081C An aerosol forming device for use in inhalation therapy
02/23/2010CA2446890C Deuterated 3-piperidinopropiophenones and pharmaceutical drugs containing these compounds
02/23/2010CA2442974C Use of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of cell proliferation diseases
02/23/2010CA2433021C Isoindole-imide compounds, compositions, and uses thereof
02/23/2010CA2403566C Use of 13-hode as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
02/23/2010CA2378880C Solutions and methods for inhibition of pain, inflammation and cartilage degradation
02/23/2010CA2374905C Pyrrolidinyl, piperidinyl or homopiperidinyl-substituted benzopyran derivatives for treating impaired fundic relaxation
02/23/2010CA2374102C Compositions containing creatine in suspension
02/23/2010CA2355834C Human akt-3
02/23/2010CA2355214C Control of arthropods in animals with use of non-emetic 1-arylpyrazoles
02/23/2010CA2353448C Improvements in or relating to powders
02/23/2010CA2345146C Cyanophenyl derivative
02/23/2010CA2339049C Treating inflammatory diseases of the head and neck with cyclooxygenase-2 inhibitors